Side by side.
Half-life, dosing, mechanism, stability — compared directly. Select up to four compounds.
Across published trials, Retatrutide shows the highest average weight loss at 24.2% (Phase 2 (NEJM 2023)), followed by Tirzepatide at 20.9% and CagriSema at 20.4%. Only Tirzepatide and Semaglutide are FDA-approved — every other compound in this table is still in trials, so its figures come from study populations rather than general use. Trials differ in length, dose and participants, so these percentages rank the compounds but are not strictly like-for-like.
Every compound, same columns.
Ordered by trial weight loss. Weight loss percentages from clinical trials. Individual results vary. Discuss options with a healthcare provider.
| Compound | Trial weight loss | Mechanism | Status | Frequency | Max dose | Trial |
|---|---|---|---|---|---|---|
| Retatrutide | 24.2% | Triple | Phase 3 ongoing | Weekly | 12mg | Phase 2 (NEJM 2023) |
| Tirzepatide | 20.9% | GLP-1/GIP | FDA Approved | Weekly | 15mg | SURMOUNT-1 (2022) |
| CagriSema | 20.4% | Amylin/GLP-1 | Phase 3 | Weekly | 2.4mg/2.4mg | REDEFINE 1 (2025) |
| Pemvidutide | 15.6% | GLP-1/Glucagon | Phase 2 | Weekly | 2.4mg | MOMENTUM (Phase 2) |
| Survodutide | 14.9% | GLP-1/Glucagon | Phase 3 ongoing | Weekly | 4.8mg | Phase 2 (Lancet 2024) |
| Semaglutide | 14.9% | GLP-1 | FDA Approved | Weekly | 2.4mg | STEP 1 (2021) |
| Mazdutide | 14.0% | GLP-1/Glucagon | Phase 3 | Weekly | 6mg | GLORY-1 (2025) |
| Orforglipron | 11.2% | GLP-1 | Phase 3 | Daily | 36mg | ATTAIN-1 (Phase 3) |
| Cagrilintide | 10.8% | Amylin | Phase 3 | Weekly | 2.4mg | REDEFINE 1 (2023) |
What each pathway does.
- GLP-1
- Glucagon-like peptide-1 reduces appetite and slows gastric emptying. The foundation of this drug class.
- GLP-1/GIP
- Adding GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion and may reduce nausea.
- GLP-1/Glucagon
- Glucagon component increases energy expenditure and may improve liver fat metabolism.
- Triple Agonist
- Combines GLP-1, GIP, and Glucagon for maximum metabolic impact across multiple pathways.
- Amylin
- Amylin analogs work on different satiety pathways, complementing GLP-1 effects.
- Combination
- CagriSema combines amylin (Cagrilintide) with GLP-1 (Semaglutide) for dual-pathway action.
Build your own comparison.
Run the side-by-side comparison tool
Pick any four compounds and compare half-life, dose envelope, benefits and risks in one view. Create a free account to use it — and to save your results, track your protocol, and pick up where you left off on any device.
Everything else on this page — the reference values, the method, and the FAQ — is free and needs no account.
These percentages come from separate trials that are not directly comparable: they ran for different durations, enrolled different populations, and used different titration schedules, so a two-point gap between two compounds may reflect trial design rather than the drug. Most of the table is still investigational — figures from a supervised trial are a poor guide to unsupervised use. Nothing here accounts for cost, availability, insurance coverage, side-effect tolerance, or your own medical history, all of which usually matter more than the ranking. For educational purposes only. Consult a healthcare provider before starting any peptide protocol.